Literature DB >> 27811073

Laboratory diagnosis of pneumonia in the molecular age.

Antoni Torres1, Nelson Lee2, Catia Cilloniz3, Jordi Vila4, Menno Van der Eerden5.   

Abstract

Pneumonia remains a worldwide health problem with a high rate of morbidity and mortality. Identification of microbial pathogens which cause pneumonia is an important area for optimum clinical management of pneumonia patients and is a big challenge for conventional microbiological methods. The development and implementation of molecular diagnostic tests for pneumonia has been a major advance in the microbiological diagnosis of respiratory pathogens in recent years. However, with new knowledge regarding the microbiome, together with the recognition that the lungs are a dynamic microbiological ecosystem, our current concept of pneumonia is not totally realistic as this new concept of pneumonia involves a dysbiosis or alteration of the lung microbiome. A new challenge for microbiologists and clinicians has therefore arisen. There is much to learn regarding the information provided by this new diagnostic technology, which will lead to improvements in the time to antibiotic therapy, targeted antibiotic selection and more effective de-escalation and improved stewardship for pneumonia patients. This article provides an overview of current methods of laboratory diagnosis of pneumonia in the molecular age.
Copyright ©ERS 2016.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27811073     DOI: 10.1183/13993003.01144-2016

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  36 in total

1.  Randomized Noninferiority Trial of Cefoperazone-Sulbactam versus Cefepime in the Treatment of Hospital-Acquired and Healthcare-Associated Pneumonia.

Authors:  Jien-Wei Liu; Yen-Hsu Chen; Wen-Sen Lee; Jung-Chung Lin; Ching-Tai Huang; Hsi-Hsun Lin; Yung-Ching Liu; Yin-Ching Chuang; Hung-Jen Tang; Yao-Shen Chen; Wen-Chien Ko; Min-Chi Lu; Fu-Der Wang
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  Performance of the extended use of the FilmArray® BCID panel kit for bronchoalveolar lavage analysis.

Authors:  Maxime Sansot; Eugénie Fradin; Rachel Chenouard; Marie Kempf; Achille Kouatchet; Sigismond Lasocki; Carole Lemarié; Matthieu Eveillard; Hélène Pailhoriès
Journal:  Mol Biol Rep       Date:  2019-02-23       Impact factor: 2.316

3.  The research agenda in VAP/HAP: next steps.

Authors:  Michael S Niederman; Ignacio Martin-Loeches; Antoni Torres
Journal:  Intensive Care Med       Date:  2017-02-14       Impact factor: 17.440

4.  Prevention and treatment of respiratory viral infections: Presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference.

Authors:  Jennifer L McKimm-Breschkin; Shibo Jiang; David S Hui; John H Beigel; Elena A Govorkova; Nelson Lee
Journal:  Antiviral Res       Date:  2017-11-21       Impact factor: 5.970

5.  Evaluation of a Novel Multiplex PCR Panel Compared to Quantitative Bacterial Culture for Diagnosis of Lower Respiratory Tract Infections.

Authors:  Mackenzie E Collins; Elena B Popowitch; Melissa B Miller
Journal:  J Clin Microbiol       Date:  2020-04-23       Impact factor: 5.948

Review 6.  Infectious Disease Complications in Patients with Cancer.

Authors:  Susan K Seo; Catherine Liu; Sanjeet S Dadwal
Journal:  Crit Care Clin       Date:  2020-11-01       Impact factor: 3.598

Review 7.  The next generation of rapid point-of-care testing identification tools for ventilator-associated pneumonia.

Authors:  Guillaume Millot; Benoit Voisin; Caroline Loiez; Frédéric Wallet; Saad Nseir
Journal:  Ann Transl Med       Date:  2017-11

Review 8.  Treating HIV-Positive/Non-AIDS Patients for Community-Acquired Pneumonia with ART.

Authors:  Catia Cillóniz; Antonella Ielpo; Antoni Torres
Journal:  Curr Infect Dis Rep       Date:  2018-09-10       Impact factor: 3.725

9.  Cost-Effectiveness Of Culture-Based Versus Empirical Antibiotic Treatment For Hospitalized Adults With Community-Acquired Pneumonia In Indonesia: A Real-World Patient-Database Study.

Authors:  Abdul Khairul Rizki Purba; Purwantyastuti Ascobat; Armen Muchtar; Laksmi Wulandari; Jan-Willem Dik; Annette d'Arqom; Maarten J Postma
Journal:  Clinicoecon Outcomes Res       Date:  2019-11-29

10.  Multicenter Evaluation of the Unyvero Platform for Testing Bronchoalveolar Lavage Fluid.

Authors:  Matthias Klein; Johannes Bacher; Sandra Barth; Faranak Atrzadeh; Katja Siebenhaller; Inês Ferreira; Stephan Beisken; Andreas E Posch; Karen C Carroll; Richard G Wunderink; Chao Qi; Fann Wu; Dwight J Hardy; Robin Patel; Matthew D Sims
Journal:  J Clin Microbiol       Date:  2021-02-18       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.